Pharmaceutical uses of polyene phosphatidyl choline for treating cognitive impairment

Abstract

The invention provides medicinal application of polyene phosphatidylcholine in treating cognitive functional disorder, which adopts a clinically commonly used medicine for protecting the liver - the polyene phosphatidylcholine to be a novel medicine for treating the cognitive functional disorder. As proved by clinical application and animal experiments, the polyene phosphatidylcholine has influence on improving the cognitive functional disorder and the memory function and has good effect of treating the cognitive functional disorder. Due to introduction of 'polyene' radicals which are more fat-soluble, the polyene phosphatidylcholine is more favorable to pass through blood-brain barriers and can be completely taken by neurons; and choline products produced by decomposition of the polyene phosphatidylcholine by the neurons can be further synthesized into acetylcholine in the neurons, thereby compensating for choline exhausted by synaptic clefts. The polyene phosphatidylcholine can generate the choline, DHA and an arachidonic acid during the process of metabolism, is a medicine for treating the cognitive functional disorder which has moderate price and small toxic and side effect, and is safe and reliable, and can also become a medicine for improving intelligence.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and relates to a new drug effect of a marketed drug, that is, the marketed drug can be used as an effective drug for cognitive dysfunction, specifically a polyene phosphatidylcholine for treating cognitive dysfunction drug use. Background technique [0002] (1) Cognitive function and cognitive impairment [0003] Cognitive function refers to various conscious and complex high-level central activities of human beings in the awakened state, including simple determination, perception, and understanding of oneself and the environment, to memory, calculation, judgment, and execution of commands, and completion of complex tasks. Cognitive dysfunction refers to different degrees of damage to cognitive function, severe cases such as various types of dementia, mild cases such as mild cognitive dysfunction. Because the latter has the value of early intervention, it has become a hot spot of internatio...

AI Technical Summary

Problems solved by technology

[0008] 1. Cholinergic receptor agonists: such as new drugs ENS163, LY246078, and DUP996, which selectively act on M1 receptors, are still in the clinical trial stage;

[0009] 2. Acetylcholine prodrugs: Substitution of Ach precursor drugs such as lecithin and choline has been tried to increase the synthesis and release of Ach, but failed to improve the central Ach function;

[0012] (1) Physostigmine: It is the earliest non-selective reversible acetylcholinesterase inhibitor used, but it has many adverse reactions and has not been approved by the FDA. It has been eliminated in clinical practice;

[0013] (2) Taccolin: It is the first non-selective reversible acetylcholinesterase inhibitor approved by the FDA. It improves cognitive function and living ability obviously, but it has serious side effects, manifested as asymptomatic increase of serum transaminase and choline Symptoms, it is rarely used clinically at present;

[0018] Through the search of the project team of the present invention on the Internet and the retrieval of domestic and foreign patent documents and published periodical papers, no report of using polyene phosphatidylcholine for the treatment of cognitive dysfunction has been seen, nor has it been found that it is related to the present invention. the same report or literature

Images